Skip to content
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP

Moderna, Inc. MRNA

10 fiscal years on record · USD · FY2025 reported · SEC filings only
$1.9B
▼ 39.9% YoY
$-2.8B
$-2.1B

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Moderna produces and sells three commercial products: Spikevax and mNEXSPIKE, its COVID-19 vaccines, and mRESVIA, its vaccine against respiratory syncytial virus. In 2025, the company achieved total revenue of $1.9 billion, largely from sales of its COVID vaccines. The company had approximately 4,700 full-time employees in 18 countries as of December 31, 2025. Over the last decade, the company has advanced a development pipeline that currently consists of 35 therapeutic and vaccine programs, 6 of which are in late-stage development. Since 2022, the company has streamlined its production sites into a global manufacturing network to support new product launches and deliver products for multi-year collaborations. Moderna, Inc. was incorporated under the laws of the State of Delaware on July 22, 2016, as successor in interest to Moderna LLC, a limited liability company formed under the laws of the State of Delaware in 2013.

Written from the business description in Moderna, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 20 February 2026. Every sentence was checked against that document before publication.

Growth

USD 1.9B
Revenue, FY2025 · full 10-year series below
Revenue $B Net income $B
FY2025 · Revenue 1.9 · Net income -2.8
10B20B-2B-4B
2016201920222025
Compound annual growth
−53.4%
+19.3%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +19.3% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−145 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -158.1% · Net -145.2%
-500%
201620202025
ROE
FY2025 · ROE -28.9%
50%100%-10%-20%-30%
201620202025
Three returns, three denominators.

Each USD of equity lost 29 cents this year.

Cash & shareholders

USD 0.00
returned in FY2025 · dividends + net buybacks
Free cash flow $B
FY2025 · FCF -2.1
5B10B-2B-3B
201620202025
Net buybacks $B Dividends $B
FY2025 · Dividends · · Net buybacks -0.0
2B3B-1B-2B
2019202020212022202320242025

Total assetsUSD 12.3B
EquityUSD 8.7B
CashUSD 2.6B
Gross debtUSD 590.0M
Net debtUSD -2.0B
Current ratio3.29×

The company holds more cash than debt.

The 10-year record

10 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
MRNA, 10-year financial record
Metric 2025202420232022202120202019201820172016
Revenue $B1.93.26.819.318.50.80.10.10.20.1
Operating income $B−3.1−3.9−4.29.413.3−0.8−0.5−0.4−0.3−0.2
EBITDA $B−2.9−3.8−3.69.813.5−0.7−0.5−0.4−0.2−0.2
Income tax $B0.1−0.00.81.21.10.0−0.00.0−0.00.0
Net income $B−2.8−3.6−4.78.412.2−0.7−0.5−0.4−0.3−0.2
Free cash flow $B−2.1−4.1−3.84.613.32.0−0.5−0.4−0.40.0
EPS, diluted $−7.26−9.28−12.3320.1228.29−1.96−1.55−4.95−4.18−3.79
Dividend / sh $◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend——————————
ROE %−28.9−28.8−28.650.3146.1−40.0−38.0———
Shares out B0.390.390.380.390.400.400.340.330.07◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

Compare

This company against its peers

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 38 reconciliationsAUDITED

Reconciled in 10 of the 10 fiscal years we could check. 20 checks were skipped: the balance sheet is not tagged before 2017. 11 checks were skipped: cost of revenue is not tagged before 2018. Nine checks were skipped: EPS is not tagged before 2016.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2016

Share this section

Download image